CARY, N.C., April 19, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Origin Biosciences, Inc., an affiliate of BridgeBio Pharma, Inc. (BridgeBio), as the exclusive specialty pharmacy provider for NULIBRY™ (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with Molybdenum Cofactor Deficiency (MoCD) Type A.
NULIBRY was approved by the U.S. Food and Drug Administration (FDA) on February 26, 2021. MoCD Type A is an ultra-rare, life-threatening genetic disorder that progresses rapidly and results in severe and largely irreversible neurological injury. Infants who survive the first few months typically have severe injuries to the nervous system with a median survival of four years. These infants have a deficiency in the production of an essential substance known as molybdenum cofactor (MoCo), leading to a lack of molybdenum-dependent enzyme activity.
NULIBRY for injection is a substrate replacement therapy that provides an exogenous source of cPMP, which is converted to molybdopterin. Molybdopterin is then converted to MoCo, which is needed for the activation of molybdenum-dependent enzymes, including sulfite oxidase, with restoration of associated activity including mitochondrial associated sulfite elimination.
“Before NULIBRY, the standard of care for MoCD Type-A was limited to supportive therapy, including the use of anti-seizure medicines,” said Ashleigh Burdette, senior director of Clinical Innovation at Biologics. “Now, MoCD Type A patients and their families have an approved therapy for the first time. We’re honored to be chosen to distribute NULIBRY, which is now FDA-approved to reduce the risk of mortality in patients with MoCD Type A. Our goal is to quickly ship NULIBRY to a hospital when MoCD Type A is suspected, because we know that for patients with this condition, every minute counts.”
“BridgeBio seeks to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers,” said Matt Outten, chief commercial officer at BridgeBio. “This is our first drug approval, and we are grateful for the opportunity to help families who are struggling with this devastating disorder. We are proud to be launching this drug in tandem with our “ForgingBridges” patient assistance program, which is designed to help patients access NULIBRY and support them throughout their treatment journey. We are committed to increasing awareness and understanding of MoCD Type A and encouraging testing as soon as MoCD Type A is suspected.”
Biologics specialty pharmacy is committed to and recognized for its level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients access treatment. This deeply skilled care team works together to develop individualized care plans that address each patient’s unique clinical, financial, and emotional needs and streamlines communication back to the treating provider. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.
Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.
Healthcare Providers may visit www.nulibry.com for more information about the product and visit www.nulibry.com/forgingbridges to learn more about the wrap-around services provided by the patient support program. Contact ForgingBridges | NULIBRY by calling 1-888-55BRIDG(E) (1-888-55-27434).
###
About Biologics by McKesson
Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.
About Origin Biosciences, Inc.
Origin Biosciences, Inc., an affiliate of BridgeBio Pharma, Inc., is a biotechnology company that developed and commercialized Nulibry for the treatment of patients with a diagnosis or presumptive diagnosis of Molybdenum Cofactor Deficiency (MoCD) Type A. Origin is led by a team of veteran biotechnology executives. For more information on Origin Biosciences, Inc., please visit the company’s website at www.origintx.com.
Contact
McKesson
Claire Crye, Public Relations
281.825.9927
claire.crye@mckesson.com